Cytokinetics CY 5031: A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

July 19, 2021
https://clinicaltrials.gov/ct2/show/NCT04944784
Amyotrophic Lateral Sclerosis ALS
Principal Investigator: Daniel S Newman, MD
Amyotrophic Lateral Sclerosis, ALS,
Accepting Participants
313-916-1906